Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in leaving the study early: acceptability ‐ leaving early due to any… compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · non response in schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with chlorprothixene (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with haloperidol (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with perphenazine (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with risperidone (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with sulpiride (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with thiothixene (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes leaving the study early: Any reason compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
1 finding from 1 review